Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium
Immunome (Nasdaq: IMNM) announced it will present a poster on the preclinical evaluation of IM-1021, a ROR1-targeted antibody drug conjugate (ADC), at the 36th EORTC-NCI-AACR Symposium in Barcelona on October 24, 2024. The presentation, titled 'Preclinical evaluation of IM-1021, a ROR1-targeted antibody-drug conjugate with a novel topoisomerase I linker payload,' will be delivered by Robert Lawrence, Director of Biology at Immunome.
The company plans to submit an Investigational New Drug (IND) application for the IM-1021 program to the FDA in the first quarter of 2025. Following the presentation, the poster will be available on Immunome's website in the 'Events & Presentations' section.
Immunome (Nasdaq: IMNM) ha annunciato che presenterà un poster sulla valutazione preclinica di IM-1021, un conjugato di farmaci ad anticorpi mirati a ROR1 (ADC), al 36° Simposio EORTC-NCI-AACR che si terrà a Barcellona il 24 ottobre 2024. La presentazione, intitolata 'Valutazione preclinica di IM-1021, un coniugato di farmaci ad anticorpi mirati a ROR1 con un nuovo payload costituito da un collegamento della topoisomerasi I,' sarà effettuata da Robert Lawrence, Direttore di Biologia di Immunome.
L'azienda prevede di presentare una domanda di Nuovo Farmaco Investigativo (IND) per il programma IM-1021 alla FDA nel primo trimestre del 2025. Dopo la presentazione, il poster sarà disponibile sul sito web di Immunome nella sezione 'Eventi e Presentazioni'.
Immunome (Nasdaq: IMNM) anunció que presentará un póster sobre la evaluación preclínica de IM-1021, un conjugado de fármacos con anticuerpos dirigidos a ROR1 (ADC), en el 36° Simposio EORTC-NCI-AACR en Barcelona el 24 de octubre de 2024. La presentación, titulada 'Evaluación preclínica de IM-1021, un conjugado de fármacos con anticuerpos dirigido a ROR1 con un novedoso payload de un enlace de topoisomerasa I,' será realizada por Robert Lawrence, Director de Biología de Immunome.
La compañía planea enviar una solicitud de Nuevo Medicamento en Investigación (IND) para el programa IM-1021 a la FDA en el primer trimestre de 2025. Después de la presentación, el póster estará disponible en el sitio web de Immunome en la sección 'Eventos y Presentaciones'.
Immunome (Nasdaq: IMNM)은 2024년 10월 24일 바르셀로나에서 열리는 제36회 EORTC-NCI-AACR 심포지엄에서 ROR1 타겟 항체 약물 접합체(ADC) IM-1021의 전임상 평가에 대한 포스터를 발표할 것이라고 발표했습니다. '신규 토포이소머라제 I 링커 페이로드가 포함된 ROR1 타겟 항체 약물 접합체 IM-1021의 전임상 평가'라는 제목의 발표는 Immunome의 생물학 디렉터인 Robert Lawrence가 진행합니다.
회사는 IM-1021 프로그램에 대한 임상시험용 의약품(IND) 신청서를 FDA에 제출할 계획입니다. 제출은 2025년 1분기에 이루어질 예정입니다. 발표 후 포스터는 Immunome 웹사이트의 '이벤트 및 발표' 섹션에서 확인할 수 있습니다.
Immunome (Nasdaq: IMNM) a annoncé qu'elle présentera un poster sur l'évaluation préclinique d'IM-1021, un conjugé médicamenteux d'anticorps ciblant ROR1 (ADC), lors du 36e Symposium EORTC-NCI-AACR à Barcelone le 24 octobre 2024. La présentation, intitulée 'Évaluation préclinique d'IM-1021, un conjugé médicamenteux d'anticorps ciblant ROR1 avec une nouvelle charge de lien de topoisomérase I,' sera réalisée par Robert Lawrence, directeur de la biologie chez Immunome.
L'entreprise prévoit de soumettre une demande de médicament expérimental (IND) pour le programme IM-1021 à la FDA au premier trimestre de 2025. Après la présentation, le poster sera disponible sur le site Web d'Immunome dans la section 'Événements et Présentations'.
Immunome (Nasdaq: IMNM) gab bekannt, dass es ein Poster zur präklinischen Bewertung von IM-1021, einem ROR1-gerichteten Antikörper-Wirkstoff-Konjugat (ADC), auf dem 36. EORTC-NCI-AACR-Symposium in Barcelona am 24. Oktober 2024 präsentieren wird. Die Präsentation mit dem Titel 'Präklinische Bewertung von IM-1021, einem ROR1-gerichteten Antikörper-Wirkstoff-Konjugat mit einem neuartigen Topoisomerase-I-Linker-Payload,' wird von Robert Lawrence, dem Direktor für Biologie bei Immunome, gehalten.
Das Unternehmen plant, einen Antrag auf ein investigational new drug (IND) für das Programm IM-1021 im 1. Quartal 2025 bei der FDA einzureichen. Nach der Präsentation wird das Poster auf der Website von Immunome im Bereich 'Veranstaltungen & Präsentationen' verfügbar sein.
- None.
- None.
Immunome expects to submit an IND for the IM-1021 program to the FDA in the first quarter of 2025.
Following the presentation, a copy of the poster will be made available in the “Events & Presentations” portion of Immunome’s website.
Poster Presentation Details:
Title: Preclinical evaluation of IM-1021, a ROR1-targeted antibody-drug conjugate with a novel topoisomerase I linker payload.
Presenter: Robert Lawrence, Director of Biology, Immunome
Date: October 24, 2024
About Immunome, Inc.
Immunome is a clinical-stage targeted oncology company committed to developing first- and best-in-class targeted therapies designed to improve outcomes for cancer patients. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge targeted cancer therapies, including antibody-drug conjugate therapies (ADCs.) In addition to a portfolio of discovery-stage ADCs, our pipeline includes AL102, a gamma secretase inhibitor which is currently in a Phase 3 trial for treatment of desmoid tumors, as well as IM-1021, a ROR1 ADC, and IM-3050, a FAP-targeted radioligand, both of which are the subject of INDs expected to be submitted in the first quarter of 2025. For more information, visit www.immunome.com.
Cautionary Statement Regarding Forward-Looking Statements
Statements in this press release that are not purely historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. We use words such as “will,” “expects,” and similar expressions to identify these forward-looking statements. These forward-looking statements include, but are not limited to, Immunome’s expected timing for submission of an IND for its IM-1021 program and other statements regarding management’s intentions, plans, beliefs, expectations or forecasts for the future. These forward-looking statements are based on Immunome’s current expectations and involve assumptions that may never materialize or may prove to be incorrect; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including, but not limited to, the risk that Immunome will not be able to realize the benefits of its strategic transactions; the risk that regulatory approvals for Immunome’s product candidates are not obtained, are delayed or are subject to unanticipated conditions; the risk that pre-clinical data may not be predictive of clinical data; the risk that Immunome’s product candidates fail to achieve their intended endpoints; and other risks and uncertainties indicated from time to time described in Immunome’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, filed with the SEC on August 12, 2024, and in Immunome’s other filings with the SEC. Except as required by law, Immunome assumes no obligation and does not intend to update any forward-looking statements included in this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241018936943/en/
Immunome Contact:
Max Rosett
Chief Financial Officer
investors@immunome.com
Source: Immunome, Inc.
FAQ
What is Immunome presenting at the 36th EORTC-NCI-AACR Symposium?
When does Immunome (IMNM) plan to submit an IND for IM-1021?
Who will present Immunome's (IMNM) poster at the EORTC-NCI-AACR Symposium?
What is the title of Immunome's (IMNM) poster presentation?
Where can investors find Immunome's (IMNM) poster after the presentation?
